Neurological Surgery 脳神経外科52巻4号

2024年07月発行

特集 髄膜腫の現在—最新の知識を活かした最善の治療のために Ⅰ 病理

髄膜腫の病理診断と遺伝子異常

著者： 湯澤明夏¹

所属機関： ¹旭川医科大学病院病理部・病理診断科

ページ範囲：P.674 - P.683

Point
・髄膜腫は多彩な組織像を示すため，発生部位や境界，造影効果，浮腫の有無などの臨床画像情報や既往歴が病理診断の上でも重要である．
・髄膜腫の病理診断にも遺伝子情報が必要になり，gradeに寄与しないものの予後と相関する遺伝子異常も複数報告されている．
・一部の遺伝子異常の検出方法として免疫組織化学が有用であるが，今後の遺伝子解析を見据えた適切なホルマリン固定が重要である．

参考文献

1）Louis DN, et al（ed）：WHO Classification of Tumours of the Central Nervous System. International Agency for Research on Cancer, Lyon, 2016

2）WHO Classification of Tumours Editorial Board：Central Nervous System Tumours. WHO Classification of Tumours, 5th Edition, Volume 6. International Agency for Research on Cancer, Lyon, 2021

3）Menke JR, et al：Somatostatin receptor 2a is a more sensitive diagnostic marker of meningioma than epithelial membrane antigen. Acta Neuropathol 130：441-443, 2015

4）Schweizer L, et al：Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein. Acta Neuropathol 125：651-658, 2013

5）Kaur S, et al：Microcystic meningioma - a diagnostic dilemma during intraoperative squash smear study. J Cytol 40：19-23, 2023

6）Sahm F, et al：TERT promoter mutations and risk of recurrence in meningioma. J Natl Cancer Inst 108：djv377, 2016　doi:10.1093/jnci/djv377

7）Sievers P, et al：CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas. Acta Neuropathol 140：409-413, 2020

8）Mirian C, et al：Poor prognosis associated with TERT gene alterations in meningioma is independent of the WHO classification：an individual patient data meta-analysis. J Neurol Neurosurg Psychiatry 91：378-387, 2020

9）Tang V, et al：Loss of p16 expression is a sensitive marker of CDKN2A homozygous deletion in malignant meningiomas. Acta Neuropathol 145：497-500, 2023

10）Sasaki S, et al：Correlation of MTAP immunohistochemistry with CDKN2A status assessed by fluorescence in situ hybridization and clinicopathological features in CNS WHO grade 2 and 3 meningiomas：a single center cohort study. J Neuropathol Exp Neurol 81：117-126, 2022

11）Spiegl-Kreinecker S, et al：TERT promoter mutations are associated with poor prognosis and cell immortalization in meningioma. Neuro Oncol 20：1584-1593, 2018

12）Wach J, et al：CDKN2A/B deletions are strongly associated with meningioma progression：a meta-analysis of individual patient data. Acta Neuropathol Commun 11：189, 2023　doi:10.1186/s40478-023-01690-y

13）Williams EA, et al：Distinct genomic subclasses of high-grade/progressive meningiomas：NF2-associated, NF2-exclusive, and NF2-agnostic. Acta Neuropathol Commun 8：171, 2020　doi:10.1186/s40478-020-01040-2

14）Driver J, et al：A molecularly integrated grade for meningioma. Neuro Oncol 24：796-808, 2022

15）Cello G, et al：Impact of H3K27 trimethylation loss in meningiomas：a meta-analysis. Acta Neuropathol Commun 11：122, 2023　doi:10.1186/s40478-023-01615-9

16）Tosefsky K, et al：Molecular prognostication in grade 3 meningiomas and p16/MTAP immunohistochemistry for predicting CDKN2A/B status. Neurooncol Adv 6：vdae002, 2024　doi:10.1093/noajnl/vdae002

17）Zschernack V, et al：p16 Immunohistochemistry as a screening tool for homozygous CDKN2A deletions in CNS tumors. Am J Surg Pathol 48：46-53, 2024

18）Berg KB, et al：Utility of methylthioadenosine phosphorylase compared with BAP1 immunohistochemistry, and CDKN2A and NF2 fluorescence in situ hybridization in separating reactive mesothelial proliferations from epithelioid malignant mesotheliomas. Arch Pathol Lab Med 142：1549-1553, 2018

19）Satomi K, et al：Utility of methylthioadenosine phosphorylase immunohistochemical deficiency as a surrogate for CDKN2A homozygous deletion in the assessment of adult-type infiltrating astrocytoma. Mod Pathol 34：688-700, 2021

20）Dono A, et al：TERT immunohistochemistry as a surrogate marker for TERT promoter mutations in infiltrating gliomas. Appl Immunohistochem Mol Morphol 31：288-294, 2023

21）Shankar GM, et al：Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. Neuro Oncol 19：535-545, 2017

22）Shankar GM, Santagata S：BAP1 mutations in high-grade meningioma：implications for patient care. Neuro Oncol 19：1447-1456, 2017

23）Williams EA, et al：Frequent inactivating mutations of the PBAF complex gene PBRM1 in meningioma with papillary features. Acta Neuropathol 140：89-93, 2020

24）Biczok A, et al：Mutational signature of extracranial meningioma metastases and their respective primary tumors. Acta Neuropathol Commun 11：12, 2023　doi:10.1186/s40478-023-01505-0

25）Prasad RN, et al：Germline BAP1 mutation in a family with multi-generational meningioma with rhabdoid features：a case series and literature review. Front Oncol 11：721712, 2021　doi:10.3389/fonc.2021.721712

26）一般社団法人日本病理学会：ゲノム診療用病理組織検体取扱い規程．2018　https://pathology.or.jp/genome_med/pdf/textbook.pdf（2024年2月24日アクセス）